For some genetic heart diseases, such as LQT syndrome, molecular genetic testing has been shown to allow prediction Background-Mutations in genes encoding for desmosomal proteins are the most common cause of arrhythmogenic right ventricular cardiomyopathy (ARVC). We assessed the value of genotype for prediction of lifetime major arrhythmic events and sudden cardiac death (SCD) in desmosomal gene-related ARVC. Methods and Results-The overall study population included 134 desmosomal gene mutation carriers (68 men; median age 36 years [22-52]) from 44 consecutive ARVC families undergoing comprehensive genetic screening. The probability of experiencing a first major arrhythmic event or SCD during a lifetime was determined by using date of birth as start point for the time-to-event analysis, and was stratified by sex, desmosomal genes, mutation types, and genotype complexity (single versus multiple mutations). One hundred thirteen patients (84%) carried a single desmosomal gene mutation in desmoplakin (n=44; 39%), plakophilin-2 (n=38; 34%), desmoglein-2 (n=30; 26%), and desmocollin-2 (n=1; 1%), whereas 21 patients (16%) had a complex genotype with compound heterozygosity in 7 and digenic heterozygosity in 14. Over a median observation period of 39 (22-52) years, 22 patients (16%) from 20 different families had arrhythmic events, such as SCD (n=1), aborted SCD because of ventricular fibrillation (n=6), sustained ventricular tachycardia (n=14), and appropriate defibrillator intervention (n=1). Multiple desmosomal gene mutations and male sex were independent predictors of lifetime arrhythmic events with a hazard ratio of 3.71 (95% confidence interval, 1.54-8.92; P=0.003) and 2.76 (95% confidence interval, 1.19-6.41; P=0.02), respectively. Conclusions-Compound/digenic heterozygosity was identified in 16% of ARVC-causing desmosomal gene mutation carriers and was a powerful risk factor for lifetime major arrhythmic events and SCD. These results support the use of comprehensive genetic screening of desmosomal genes for arrhythmic risk stratification in ARVC.
A rrhythmogenic right ventricular cardiomyopathy (ARVC)
is an inheritable heart muscle disease characterized by fibrofatty replacement of the right ventricular (RV) myocardium. 1, 2 The natural history of ARVC is predominantly related to RV electric instability with ventricular tachycardia (VT) and ventricular fibrillation leading to sudden cardiac death (SCD). [3] [4] [5] [6] Studies of molecular genetics have provided significant insights in our understanding of the pathogenesis and pathophysiology of ARVC, showing that, in its pure form, it is a genetic disorder of intercellular junctions resulting from mutations of genes that encode for desmosomal proteins such as plakoglobin (JUP), desmoplakin (DSP), plakophilin-2 (PKP-2), desmoglein-2 (DSG-2), and desmocollin-2 (DSC-2). [7] [8] [9] [10] [11] [12] [13] [14] A few additional causative mutations have also been identified in nondesmosomal genes. 8, 15 The discovery of desmosomal gene mutations involved in the disease pathogenesis has offered the potential of a molecular genetic diagnosis of ARVC in the clinical setting. 16 of arrhythmic risk and genotype-based optimization of therapy. 17 At present, the prognostic impact of genotype in ARVC patients remains poorly understood, and the arrhythmic risk stratification relies on phenotypic predictors, including young age at time of diagnosis, previous cardiac arrest or syncope, VT, severe RV or left ventricular (LV) dysfunction, and inducibility at programmed ventricular stimulation. 18 Previous genotype-phenotype correlation studies failed to identify specific genes or mutations distinctively associated with an unfavorable arrhythmic outcome, and to date, there is little evidence to support the use of genetic screening for prognostic assessment. 19 More recent studies, based on comprehensive analysis of ARVC-causative desmosomal genes, reported that compound heterozygosity (coinheritance of different disease alleles of a single gene) and digenic heterozygosity (coinheritance of disease alleles for 2 different genes) is not uncommon and may contribute significantly to varying ARVC penetrance and expression. [20] [21] [22] [23] [24] However, a systematic evaluation of the genetic predictors of lifetime arrhythmic outcome and SCD has not been previously performed. Such information would be useful in making decision about treatment, particularly for asymptomatic individuals. 7 Thus, the present study was designed to evaluate the impact of genotype, with particular reference to a complex genetic status with multiple desmosomal gene mutations, to predict the probability of experiencing a first major arrhythmic event, including SCD, after birth in a consecutive series of ARVC desmosomal gene mutation carriers. The evaluation of a gene-dose effect of compound/digenic status on the lifetime arrhythmic risk was made possible by the comprehensive genetic analysis of all known ARVC-causing desmosomal genes.
Methods

Study Sample
Patient cohort for this single-institution study was drawn from the Inherited Arrhythmogenic Cardiomyopathy Unit of the Department of Cardiac, Thoracic, and Vascular Sciences of the University of Padua, Italy, which is a national referral center for the diagnosis and management of ARVC patients.
The initial cohort comprised 90 unrelated living probands with a clinical diagnosis of ARVC based on the 2010 International Task Force (ITF) criteria, 25 who underwent comprehensive molecular screening of desmosomal genes. One or more causative mutations of desmosomal genes were found in 44 (49%) ARVC probands. Mutation screening of living family members (N=217) of the 44 genotype-positive probands identified other 90 (41%) desmosomal gene mutation carriers. Overall, the population of the present study included 134 desmosomal gene mutation carriers (44 probands and 90 family members) from 44 consecutively genotyped ARVC families. Of these 44 families, 16 were reported in an earlier investigation with a different study design and end point. 20 The study was approved by the institutional review board, and all subjects gave their informed consent.
Clinical Evaluation
Clinical evaluation included detailed personal and family histories, physical examination, 12-lead ECG recording, chest x-ray, signalaveraged ECG, 24-hour Holter monitoring, exercise testing, and 2-dimensional transthoracic echocardiography. Sixty-three patients (46%) underwent additional imaging studies such as contrastenhanced cardiac magnetic resonance or cardiac catheterization, including RV and LV cineangiography; 38 (28%) patients were studied by intracardiac electrophysiological study, including programmed ventricular stimulation.
According to the 2010 ITF criteria, 25 the diagnosis of definite ARVC was fulfilled in the presence of either 2 major criteria, 1 major criterion plus 2 major criteria, or 4 minor criteria from different categories. ARVC diagnosis was considered borderline when 1 major and 1 minor criterion or 3 minor criteria from different categories were fulfilled.
Mutation Screening
A comprehensive open reading frame/splice site mutational analysis of all amino acid coding exons and intron boundaries of the 5 ARVC-susceptible desmosomal genes has been performed as previously described. 20 According to the 2010 ITF criteria, 25 a pathogenetic mutation was defined as a DNA alteration previously associated with ARVC that was unobserved or rare in a large, non-ARVC, ethnically matched control population and was predicted to alter the structure or the function of the encoded protein or cosegregated with disease phenotype in the family. All other sequence variants were classified as polymorphisms. 26 All DNA-identified variants were compared with a control group of >300 unrelated, healthy individuals (600 alleles) from the white population. Mutations were classified into missense and nonmissense (ie, nonsense, frameshift, and splice mutations). Multiple mutations were coded as a binary variable (either single or multiple mutations).
All subjects gave written informed consent after counseling in accordance with the ethical standards of the Declaration of Helsinki (2001) and with recommendations given by the Institutional Ethical Committee.
Lifetime Arrhythmic Outcome and End Points
Because ARVC desmosomal gene mutation carriers are exposed to the genetic risk of life-threatening ventricular arrhythmias and SCD from birth, the genotype-related arrhythmic risk assessment was based on the cumulative probability of experiencing a first arrhythmic event or SCD during life-time using date of birth as start point for the time-to-event analysis. 17 Medical history of each subject was obtained by review of medical records, clinical evaluation, and patients' interviews during regular outpatient visits (at intervals of 6-12 months). For each subject, the follow-up period extended to the most recent evaluation or censoring event up to June 2012.
The end point for the survival analysis was composite and included first major arrhythmic event occurring during follow-up, such as SCD, aborted SCD because of ventricular fibrillation (VF), sustained VT, and appropriate intervention of implantable cardioverter-defibrillator (ICD). SCD was defined as any natural death occurring instantaneously or within 1 hour from symptoms onset. Aborted SCD was defined as successful cardiopulmonary resuscitation/defibrillation for cardiac arrest due to ventricular fibrillation. Appropriate ICD intervention was defined as an ICD shock delivered in response to VT or VF and documented by stored intracardiac ECG data, as previously reported. 6
Statistical Analysis
Results are summarized as means or n (%) for continuous and categorical variables, respectively. Categorical differences between groups were evaluated by χ 2 test or Fisher exact test as appropriate. Continuous variables were expressed as median (25 to 75 percentiles) and compared with Wilcoxon rank-sum test or Kruskal-Wallis test. The cumulative probability of experiencing a first arrhythmic event during life-time was determined by using date of birth as the start point for the time-to-event analysis. Subjects were censored at the time of their first event or the time of their last clinical follow-up. Survival distribution during life-time of the composite arrhythmic end point was estimated using Kaplan-Meier curves.
Effect of covariates on time to composite arrhythmic end point were investigated using a Cox proportional hazard model. Hazard ratio and 95% confidential intervals (CIs) were always presented.
Inflation in standard error due to familiar correlation of subjects was taken into account using a Huber-White (sandwich) estimator implemented in the RMS Libraries of the R system, 27 as described by Harrell. 28 Proportionality of hazards was assessed visually using Shoenfeld residual plots.
Because of the small sample size, multivariable models were built using a forward approach and adopting Akaike Information Criterion as selection criterion. A significance of 0.10 was required for variables to be candidates for the model. Model validation was performed using bootstrap (1000 resamples) and Somers Dxy as measure of fitting adequacy. A value of P<0.05 was taken as a threshold for statistical significance.
All analyses have been performed using SPSS version 17 (SPSS Inc., Chicago, IL) and the R system.
Results
The study population included 134 desmosomal gene mutation carriers (68 men; median age 36 years ) whose clinical characteristics at the time of last evaluation are reported in Table 1 . Four patients had been involved in competitive sports activity before diagnosis of ARVC or genotyping. Prophylactic antiarrhythmic drug/β-blocker therapy for primary prevention of life-threatening arrhythmias was prescribed in 47 (35%) patients; 25 (19%) patients were implanted with an ICD, either for secondary (N=22) or primary (N=3) prevention.
Desmosomal Gene Mutations
Mutations identified by comprehensive sequencing of desmosomal genes are summarized in Table 2 . A total of 48 desmosomal gene mutations absent in ≥600 reference alleles were found. Among them, 16 were nonmissense mutations.
A single pathogenetic mutation was identified in 113 patients (84%) with the following gene distribution: DSP, n=44 (39%); PKP-2, n=38 (34%), DSG-2, n=30 (26%); and DSC-2, n=1 (1%). None carried JUP mutations. Of the 113 patients, 62 carried missense mutations, and 51, nonmissense mutations.
A complex genetic phenotype with multiple desmosomal gene mutations was detected in 21 carriers (16%): compound heterozygosity in 7 and digenic heterozygosity in 14 (for details on multiple desmosomal gene mutations, see Table 3 ).
Disease Penetrance
Of the 134 desmosomal gene mutation carriers, 78 (58%) fulfilled the 2010 ITF criteria for definite or borderline ARVC (Table 4 ). Disease penetrance was higher in patients with multiple mutations than in those with single mutations (17 of 21 versus 61 of 113; P=0.03); the difference remained statistically significant after adjustment for age and sex (odds ratio, 3.1; 95% CI, 1.2-9.1; P=0.03). Among patients with single mutation, disease penetrance did not differ according to specific desmosomal genes or to the presence of missense versus nonmissense mutations.
Phenotypic Expression
Among the 78 patients with borderline or definite disease, men significantly more often showed low QRS voltages in limb leads (42% versus 26%; P=0.04) and LV dysfunction with ejection fraction <55% (28% versus 8%; P=0.02). The presence of multiple desmosomal gene mutations was associated with: (1) more frequent ECG abnormalities in the form of ε-waves (39% versus 8%; P=0.001), right precordial negative T-waves extending beyond lead V3 (56% versus 26%; P=0.02), and late potentials on signal-averaged ECG (89% versus 64%; P=0.04); and (2) more severe echocardiographic alterations as shown by a lower mean RV fractional area change (21 [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] versus 29 [24] [25] [26] [27] [28] [29] [30] [31] ; P=0.001) and a higher prevalence of multiple RV wall motion abnormalities (≥2 regions; 72% versus 39%; P=0.01).
In the subgroup of 61 patients with single mutation who fulfilled the ITF criteria for either borderline or definite ARVC, carriers of single nonmissense mutations significantly more often had right precordial T-wave inversion extending beyond lead V3 (45% versus 13%; P=0.006) and showed a trend toward a lower mean RV fractional area change (27 [20-30] versus 30 [27] [28] [29] [30] [31] [32] ; P=0.06) compared with carriers of single missense mutations. No statistically significant differences in the clinical phenotype were attributable to specific desmosomal genes, with the exception of DSP gene mutation carriers who distinctively had more frequent negative T-waves confined to leads V4 to V6 (DSP 9% versus PKP-2, DSG-2, DSC-2 0%; P=0.02), low QRS voltages in limb leads (DSP 57% versus PKP-2 18%, DSG-2 17%, DSC-2 0%; P=0.02), and LV dysfunction with ejection fraction <55% (DSP 38%, DSG-2 10%, PKP-2 6%, DSC-2 0%; P=0.01). 
Symptoms
Palpitations, n (%) 37 (28) Chest pain, n (%) 11 (8) Syncope, n (%) 7 (5)
ECG findings
Low QRS voltage in limb leads, n (%) 30 (22) ε-Waves, n (%) 12 (9) Negative T-wave in leads V1-V2/V3 only, n (%) 15 (11) Negative T-wave beyond lead V3, n (%) 28 (21) Negative -4 ).
There were 12 events among the 44 probands (27%) and 10 events among the 90 family members (11%). No subject who experienced arrhythmic events had been previously involved in a competitive sports activity. Subjects with and without major arrhythmic events during follow-up did not differ with regard to prophylactic antiarrhythmic drug/β-blocker therapy, which had been prescribed for primary prevention of life-threatening arrhythmias (8 of 22, 36% versus 39 of 112, 35%; P=0.89).
Kaplan-Meier analysis of freedom from major arrhythmic events from date of birth stratified by sex, genetic locus, type of mutation, and number of desmosomal gene mutations is reported in Figures 1 to 4 .
On multivariable Cox regression analysis, multiple gene mutations and male sex remained independent risk factors for lifetime occurrence of major arrhythmic events, with hazard ratios of 3.71 (95% CI, 1.54-8.92) and 2.76 (95% CI, 1.19-6.41), respectively (Table 5) , showing a good model adequacy (Somers Dxy=0.71).
Male patients carrying multiple mutations were at the highest risk (63% life-time rate of events), followed by women with multiple mutations (27%), men with single mutation (13%), and women with single mutation (7%; Figure 5 ). The median observation period was similar in the 4 subgroups (44 years [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] 
Family History of Premature SCD
In the history of 44 families, premature SCD (<35 years) had occurred in 12 subjects (10 men). Of 12 SCD victims, 9 (75%) belonged to families with a complex genotype ( Table 6 ).
Discussion
To our knowledge, this is the first study designed to assess the value of genotype to predict the cumulative probability of experiencing a first major arrhythmic event during a lifetime in desmosomal gene-related ARVC. The major study results were that compound/digenic heterozygosity was identified in 16% of our cohort of ARVC desmosomal gene mutation carriers. This complex genetic status was a powerful and independent risk factor of malignant arrhythmic events and SCD during life-time. The study results support the use of comprehensive molecular screening of desmosomal genes in ARVC not only for early diagnosis, but also for arrhythmic risk stratification and optimization of therapeutic interventions aimed to prevent SCD, particularly in individuals who are asymptomatic.
Genotype-Phenotype Correlations
Molecular genetic diagnosis of ARVC by screening for mutations in desmosomal genes is successful in ≈45% of patients. 16, 19 Diagnostic genetic testing is applied to probands with a clinical suspicion of ARVC with the aim of establishing a definitive diagnosis. Identification of a pathogenetic desmosomal gene mutation in the proband enables cascade family screening, which offers the potential of a preclinical diagnosis among relatives and allows to target resources to proven ARVC mutation carriers. [20] [21] [22] [23] [24] 29 The value of underlying molecular genetic cause for risk stratification of ARVC patients remains poorly understood, and current management guidelines for patients with ARVC give little consideration to the prognostic impact of molecular genotyping. 19 Most of previous genotype-phenotype correlation studies were based on a few families, separately addressed mutations in different desmosomal genes, and compared clinical manifestations of ARVC mutation carriers versus noncarriers. 30, 31 Although some differences have been reported with regard to a series of clinical, ECG, and morphofunctional RV abnormalities in variables between ARVC gene-positive and gene-negative patients, detection of ARVC desmosomal gene mutations was not associated with an enhanced susceptibility to life-threatening arrhythmias and did not predict arrhythmic outcome compared with an unknown genotype. Few available studies correlating the phenotype to the underlying genotype provided contradictory findings with regard to the association between specific desmosomal genes or mutation and clinical features. A specific trend toward more prevalent LV involvement was attributed to DSP mutations by Quarta et al, 23 and to DSG-2 mutations by Fressart et al, 22 whereas no association was reported by others. 21 In our study, we found that DSP mutation carriers distinctively exhibited a more prevalent LV involvement. However, in accordance with previous studies, neither nonmissense mutations nor mutations in a particular desmosomal gene were able to predict an unfavorable arrhythmic outcome of ARVC patients.
Genotype Complexity
Recent reports indicate that a sizeable proportion of ARVC patients carry >1 gene mutation (ie, compound and digenic heterozygosity), which may contribute to varying ARVC penetrance and expression. [20] [21] [22] [23] [24] Xu et al 24 reported that missense mutations of desmosomal genes, mostly PKP-2, although relatively common in ARVC probands, may be not enough for the disease phenotype to be overt and require additional mutation(s). In this study, subjects harboring >1 variant in PKP2 or PKP2 plus other desmosomal gene variants had a more penetrant and expressed disease with an earlier onset. Quarta et al 23 reported that ARVC probands were significantly more likely than first-degree relatives to harbor >1 rare genetic variant; within families, diallelic individuals more often developed disease expression and became the first family member to receive a diagnosis, whereas among relatives, the presence of >1 rare genetic variant was associated with a significant (5-fold) increase in risk of disease expression. Likewise, in the study by Bauce et al, 20 multiple mutation carriers showed a significantly higher prevalence of ECG repolarization changes and LV involvement, but no worse arrhythmic outcome during a short-term follow-up. Hence, the present study was specifically designed to assess as primary end point the value of genotype to predict the cumulative probability of experiencing a first major arrhythmic event and SCD since birth in desmosomal gene-related ARVC. Compound/digenic heterozygosity was identified as the most important genetic determinant of malignant arrhythmic outcome since birth.
We found that compound and digenic heterozygosity was present in 16% of cases. This overall rate for multiple mutations was greater than in previous studies from other countries where the reported prevalence of multiple mutations did not exceed 10% of cases. [21] [22] [23] [24] In agreement with previous studies, carriers of multiple mutations showed a more penetrant disease and more severe phenotypic expression. However, our study results extended previous observations by showing a gene-dose arrhythmic effect, given that multiple desmosomal gene mutations were the most powerful genetic predictor of composite arrhythmic end point. Complex genotype identified ARVC patients at increased risk of life-time major arrhythmic events/SCD and remained an independent determinant of malignant arrhythmic outcome during life-time at multivariable analysis.
According to the study design, our study population was limited to living probands or relatives who underwent a comprehensive screening of desmosomal genes implicated in the ARVC cause. Subjects who experienced SCD at young age (<35 years) before undergoing genetic analysis were unavoidably not included in the analysis of genetic predisposition to life-time arrhythmic events and SCD. However, it is noteworthy that the majority (75%) of these young SCD victims belonged to families with multiple mutations, which further suggests an association between complex genotype and increased risk of fatal arrhythmic events.
The precise mechanism underlying a more malignant arrhythmic course in patients carrying multiple desmosomal gene mutations is speculative. Whether worse ventricular electric instability is secondary to a genetically determined greater extent of ventricular fibrofatty myocardial scar 32 or it results directly from molecular defects of desmosomes or abnormal gap junction/sodium channel interactions 3, 33, 34 remains to be elucidated by further studies.
Sex
Previous studies on ARVC index cases consistently demonstrated a male predominance, suggesting that men develop a more severe disease phenotype, making them more likely to come to medical attention. 21, 30, 35, 36 Although in the present study multiple mutations had the single most important role in predicting arrhythmic events, this factor was importantly modulated by male sex. Arrhythmic prognosis was worse in male desmosomal gene mutation carriers, and men with multiple mutations exhibited the highest cumulative risk (63%) of experiencing a malignant arrhythmic event. In addition, Kaplan-Meier analysis showed that desmosomal gene carriers remained arrhythmia-free for a long period of time, with events occurring after pubertal development. This finding is in agreement with a previous study showing that the majority of familial cases are not diagnosed in infancy and that both ARVC clinical onset and arrhythmic events are characteristically delayed to adolescence and young adulthood, with a peak at the age interval of 15 to 35 years. 35, 37 All these findings suggest a direct influence of sex hormones on disease pathobiology and development of arrhythmogenic myocardial substrate. In this regard, estrogens, such as 17-β-extradiol, at physiological concentration exert an inhibitory effect on myocardial cell apoptosis, 38 which has been shown to play a role in myocyte death and subsequent fibrofatty myocardial replacement in ARVC. 39 This protective effect of estrogens may partly explain why females with desmosomal gene mutations tend to develop a less severe disease phenotype and fewer arrhythmic complications compared with males.
Study Limitations
Sequence alterations were divided into pathogenic mutations and polymorphisms according to generally accepted criteria. 25 Recent studies on the presence of desmosomal gene variants in the general population demonstrated that although nonmissense desmosomal gene variants are high-probability, ARVCcausing mutations, the pathogenetic potential of rare missense mutations should be interpreted with greater caution and in the context of race and ethnicity, mutation location, and sequence conservation. 26, 40 In vitro functional analysis or animal studies would have been required to conclusively proof the causative nature of missense variants. However, it is important to stress that these limitations are exactly the same as present in all previous genotype-phenotype studies in ARVC.
Although genetic and sex-linked hormonal factors may play a primary role, greater risk of developing life-threatening ventricular arrhythmias may be related to environmental factors, such as prolonged and intense physical activity that may influence disease phenotype and outcome. It is believed that the incorporation of genetically defective proteins into cardiac desmosomes may provoke detachment of myocytes at the intercalated discs, 41 particularly under conditions of mechanical stress such as that occurring during regular and vigorous sports training/competition. 8 Therefore, one may expect that the more intensively a given subject is involved in physical activity in the teen years, the more severe the ventricular fibrofatty scar lesion and the more malignant the arrhythmic disease manifestations. However, in our study, the poorer arrhythmic outcome in multiple mutation carriers than in single mutation carriers cannot be related to sports performance, because none of the former group was involved in competitive sports.
Clinical Implications and Conclusion
According to the results of the present study, compound/ digenic heterozygosity of ARVC-causing desmosomal gene mutations predicts a more severe arrhythmic outcome because of a double-dose effect. This highlights the importance of screening the entire panel of desmosomal genes even after a single gene mutation has been identified. Moreover, the occurrence of double and compound mutations and the increased chances of inheriting the gene defect have significant implications for genetic counseling. If a subject is a double heterozygote with a mutation on 2 different desmosomal genes inherited independently, the risk that a child will receive ≥1 gene mutation is 75%, whereas the chance of inheriting both gene mutations is 25%. In subjects with a compound heterozygosis, there is a 50% risk of passing on the multiple gene defects if the 2 mutations are both on the same allele (cis), and a 100% risk of transmitting 1 of the 2 mutations if they are on different alleles (trans). Cardiologists and clinical/medical geneticists dealing with ARVC families should be skilled in offering an appropriate genetic counseling to elucidate and discuss the patterns of inheritance and clinical consequences of multiple mutations, which may assist couples in making a more informed decision about prenatal genetic testing and management of pregnancy.
In addition, our study provides insights on presymptomatic arrhythmic risk stratification for SCD in ARVC. Clinical manifestations of ARVC usually develop during adolescence or young adulthood and are preceded by a long preclinical phase. 7, 8, 35 Cardiac arrest may occur as the first manifestation of disease in previously asymptomatic adolescents and young adults. 1, 2 The most important aim of genotyping families with ARVC is to diagnose genetically affected relatives before a malignant clinical phenotype can occur. According to our results, demonstration of multiple desmosomal gene mutations on genotyping may be a major factor predicting lifethreatening arrhythmias. Preclinical identification of young individuals carrying multiple desmosomal gene mutations can lead to establishing a focused prevention strategy with a closer clinical follow-up and a more aggressive treatment. It is reasonably to assume, on the basis of our findings, that lifestyle modifications, such as restriction from competitive sport and prophylactic therapy with β-blockers, are indicated in carriers of multiple desmosomal gene mutations, particularly men who have the highest arrhythmic risk. By contrast, the decision to institute prophylactic therapy in single mutation carriers, particularly women, at lower risk of events is not justified and should be individualized. Whether a lower threshold for ICD therapy should be used among asymptomatic carries of multiple desmosomal gene mutations remains to be established by larger cohort studies.
